🇺🇸 FDA

Intelligence Platform

Patents

Browse 837 pharma-relevant US patents (A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 12012445

Anti-VEGF protein compositions and methods for producing the same

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jun 18 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 13 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12012444

Anti-VEGF protein compositions and methods for producing the same

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jun 18 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 13 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12010979

Non-human animals comprising a humanized TTR locus and methods of use

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jun 18 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 13 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11999799

Anti-TMPRSS2 antibodies and antigen-binding fragments

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jun 04 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 30 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12000839

Methods for characterizing disulfide bonds

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jun 04 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 30 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11999777

Methods for treating or preventing SARS-CoV-2 infections and COVID-19 with anti-SARS-CoV-2

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jun 04 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 30 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11986511

Use of a VEGF antagonist to treat angiogenic eye disorders

REGENERON PHARMACEUTICALS, INC. · Granted Tue May 21 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 16 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11975045

Use of a VEGF antagonist to treat angiogenic eye disorders

REGENERON PHARMACEUTICALS, INC. · Granted Tue May 07 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 02 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11964016

Combination of IL-4/IL-13 pathway inhibitors and plasma cell ablation for treating allergy

REGENERON PHARMACEUTICALS, INC. · Granted Tue Apr 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11965020

Antigen binding molecule formats

REGENERON PHARMACEUTICALS, INC. · Granted Tue Apr 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11965161

Methods and compositions for sensitization of tumor cells to immune therapy

REGENERON PHARMACEUTICALS, INC. · Granted Tue Apr 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11957704

Methods of treating metabolic disorders and cardiovascular disease with inhibin subunit be

REGENERON PHARMACEUTICALS, INC. · Granted Tue Apr 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11958894

Anti-VEGF protein compositions and methods for producing the same

REGENERON PHARMACEUTICALS, INC. · Granted Tue Apr 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11958910

Bispecific antigen binding molecules that bind HER2, and methods of use thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Apr 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11957687

Modulators of HSD17B13 and methods of use thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Apr 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11951216

Polymer protein microparticles

REGENERON PHARMACEUTICALS, INC. · Granted Tue Apr 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11945872

Anti-ACVR1 antibodies and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Apr 02 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11944666

Treatment of inflammatory conditions delivery of interleukin-1 receptor antagonist fusion

REGENERON PHARMACEUTICALS, INC. · Granted Tue Apr 02 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11932692

Methods of treating cancer pain by administering a PD-1 inhibitor

REGENERON PHARMACEUTICALS, INC. · Granted Tue Mar 19 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11926670

Stabilized formulations containing anti-interleukin-4 receptor (IL-4R) antibodies

REGENERON PHARMACEUTICALS, INC. · Granted Tue Mar 12 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11926668

Anti-PD-1 antibodies for treatment of lung cancer

REGENERON PHARMACEUTICALS, INC. · Granted Tue Mar 12 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11926661

Human antibodies to artemin and methods of use thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Mar 12 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11919965

Methods of treating multiple myeloma with bispecific anti-BCMA x anti-CD3 antibodies

REGENERON PHARMACEUTICALS, INC. · Granted Tue Mar 05 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11919972

Peptide libraries with non-canonical amino acids

REGENERON PHARMACEUTICALS, INC. · Granted Tue Mar 05 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted